Immuno-Oncology | Specialty

Experts Grapple With Nuances of Navigating New Frontier in Melanoma

January 13th 2016

Questions remain in terms of how to optimally sequence and/or combine both targeted agents and immunotherapies in melanoma.

Dramatic Changes on Horizon in Renal Cell Carcinoma

January 12th 2016

The optimal frontline treatment strategy for patients with metastatic renal cell carcinoma could look dramatically different in the next few years, as studies assess combination strategies and predictive biomarkers for immunotherapy and targeted therapies.

Hope Rugo on Pembrolizumab's Potential in ER+/HER2- Breast Cancer

January 12th 2016

Hope Rugo, MD, discusses the phase Ib KEYNOTE-028 trial and the impact of its results thus far, as well as the design, findings, and next steps for the trial.

Dr. Burtness on Emerging Immunotherapies in Head and Neck Cancer

January 12th 2016

Barbara A. Burtness, MD, professor of Medicine (Medical Oncology), clinical research program leader, Head and Neck Cancers Program, co-director, Developmental Therapeutics Research Program, Yale Cancer Center, discusses emerging immunotherapies and ongoing clinical trials in head and neck cancer.

Atezolizumab/Vemurafenib Combo Shows Clinical Activity in BRAF+ Melanoma

January 12th 2016

The combination of atezolizumab (MPDL3280A) and vemurafenib (Zelboraf) yielded durable responses in patients with previously untreated BRAF V600–mutated metastatic melanoma in an ongoing phase Ib study.

Nivolumab's Survival Benefit Sustained Across RCC Subgroups

January 11th 2016

Nivolumab’s second-line survival benefit in renal cell carcinoma was consistent across subgroups categorized by patient risk status, prior treatment, and degree of metastases, according to an update of the phase III CheckMate-025 trial.

Atezolizumab Update Affirms Activity in Bladder Cancer

January 9th 2016

Second-line treatment with atezolizumab (MPDL3280A) led to durable responses in patients with locally advanced or metastatic urothelial carcinoma.

First Checkpoint/Chemo Combo Study for Urothelial Cancer Falls Short

January 9th 2016

The addition of the CTLA-4 inhibitor ipilimumab to cisplatin and gemcitabine did not significantly improve overall survival for patients with metastatic urothelial cancer.

Avelumab Spurs Responses in Refractory Metastatic Urothelial Cancer

January 9th 2016

The investigational anti-PD-L1 antibody avelumab demonstrated antitumor activity with an acceptable safety profile in a phase Ib trial of patients with metastatic urothelial cancer refractory to standard therapy.

Dr. Elizabeth Plimack on Immunotherapy Potential in Bladder Cancer

January 9th 2016

Elizabeth Plimack, MD, MS, Associate Professor, Director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses immunotherapy in bladder cancer.

Dr. Choueiri on Significance of CheckMate-025 Study for RCC

January 8th 2016

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the significance of the CheckMate-025 for renal cell carcinoma.

Dr. Formenti on Combining Radiotherapy With Immunotherapy in NSCLC

January 7th 2016

Silvia Formenti, MD, chair of Radiation Oncology at Weill Cornell Medical College and radiation oncologist-in-chief at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses combining radiotherapy with immunotherapy in non-small cell lung cancer (NSCLC).

Jason Luke on Significance of Biomarker Development for Immunotherapy in Melanoma

January 7th 2016

Jason J. Luke, MD, discusses potential new methods for determining prognostic markers in melanoma and the challenges of balancing toxicity with efficacy in designing combination regimens.

Dr. Arlene Sharpe on the Role of the PD-1 Pathway

January 7th 2016

Arlene Sharpe, MD, PhD, immunology faculty member, Harvard Medical School, discusses the biology of the PD-1 pathway.

Nivolumab Continues to Improve Outcomes in Advanced Melanoma

January 6th 2016

Victoria Atkinson, MD, discusses the impact of the phase III CheckMate-066 trial and nivolumab’s future as both a monotherapy and in combination with other therapies.

Expert Discusses Promising Pembrolizumab Triplet in Advanced Myeloma

January 5th 2016

Jesus San Miguel, MD, PhD, discusses a phase I study examining pembrolizumab added to lenalidomide and low-dose dexamethasone in patients with heavily pretreated relapsed/refractory multiple myeloma, while emphasizing the need for further follow-up.

Dr. Luke on the Future of Combination Therapy in Melanoma

January 5th 2016

Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses what the future holds for combination therapies for patients with melanoma.

Leading Checkpoint Researcher Optimistic About New Targets

December 29th 2015

Thomas F. Gajewski, MD, PhD, discusses how the field of immune checkpoints is expanding beyond PD-1 and CTLA-4.

PD-1 Success Fuels Interest in Many Immune System Targets

December 28th 2015

It is becoming increasingly clear that PD-1/ PD-L1 and CTLA-4 represent just the tip of the iceberg when it comes to manipulating the immune system to fight cancer, and the number of known checkpoints—and with it the list of potential drug targets—has expanded in recent years.

Importance of BRAF Testing Grows as Options Expand in Melanoma

December 28th 2015

As clinical experience grows with new agents, combinations, and sequences of therapy, the use of molecular profiling in metastatic melanoma is likely to become an essential means of choosing among treatment options.

NEXT PAGE
PREVIOUS PAGE